What should the investigator review and endorse at important milestones?

Boost your GCP E6 (R3) exam readiness. Improve your understanding with engaging, insightful questions. Test yourself with hints and detailed explanations. Prepare effectively!

Multiple Choice

What should the investigator review and endorse at important milestones?

In good clinical practice, investigators review and endorse the data at important milestones to ensure that decisions about the trial are based on accurate information. The interim data and ongoing results are used to assess safety, efficacy signals, and overall trial conduct. By reviewing and endorsing these reports, the investigator affirms that the data have been collected, recorded, and analyzed according to the protocol and data management plan, and that any safety concerns have been evaluated. This endorsement supports appropriate decisions about continuing, modifying, or stopping the trial and ensures accountability for the integrity of the study. Final bibliography, site visit schedule, and focusing only on the protocol version do not directly address ongoing data integrity and safety review at key milestones. The data being reviewed during interim analysis is the element that directly informs trial progress and participant safety.

In good clinical practice, investigators review and endorse the data at important milestones to ensure that decisions about the trial are based on accurate information. The interim data and ongoing results are used to assess safety, efficacy signals, and overall trial conduct. By reviewing and endorsing these reports, the investigator affirms that the data have been collected, recorded, and analyzed according to the protocol and data management plan, and that any safety concerns have been evaluated. This endorsement supports appropriate decisions about continuing, modifying, or stopping the trial and ensures accountability for the integrity of the study.

Final bibliography, site visit schedule, and focusing only on the protocol version do not directly address ongoing data integrity and safety review at key milestones. The data being reviewed during interim analysis is the element that directly informs trial progress and participant safety.

More practice questions